Crucell
Crucell is a biotechnology company specializing in vaccines and biopharmaceutical technologies.
 | |
| Privately held naamloze vennootschap; subsidiary | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Leiden, Netherlands |
Key people | Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board) |
| Products | Vaccines and antibodies |
| Owner | Johnson & Johnson |
| Website | www.crucell.com |
In September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[1] J&J acquired the rest of the company in October 2010, taking its stake to over 95% by February 2011[2] and delisting the company from stock exchanges two months later.[3]
References
- Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009.
- Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011.
- Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.